1.. Introduction {#s0001}
================

Wound healing within the oral cavity context is an extremely complex mechanism where multiple characters may intervene, such as cell and/or tissue interrelations, growth factors and salivary components.

The history of dental dressings dates back to 1923 when Ward introduced 'Wondrpack' with the aim of protecting the surgical site, splinting of soft tissue and mobile teeth, immobilization of the surgical site, preventing tooth hypersensitivity and enhancing patient comfort (Ward, [@CIT0044]). Wound healing involves a sequence of molecular and cellular events including inflammation, cell migration, angiogenesis, extracellular matrix synthesis, and re-epithelialization. Principally, inflammation is a protective response to eliminate the initial cause of cell injury as well as necrotic cells and tissues resulting from the original insult. The inflammatory response is terminated when the injuries stimulus is removed and the inflammatory mediators have been dissipated, catabolized, or inhibited. Thus, healing begins very early in the process of inflammation (Martin et al., [@CIT0025]), therefore, it is important to explore biomaterials and dressings to promote wound healing in the shortest time possible. In 1984, a review article discussed the positive effects of periodontal dressings. Sachs, in this article, explained the benefits of dressing for minimizing the risk of postoperative complications such as wound infection and bleeding, enhancing tissue healing by preventing physical trauma during mastication and speech and inhibiting granulation tissue formation (Sachs et al., [@CIT0040]). It was long believed that covering the surgical site with periodontal dressing prevents microbial infections by decreasing plaque accumulation. The possibility to reduce post-surgical pain is among the main reasons for clinicians to cover the surgical site with dressing (Ghanbari et al., [@CIT0017]).

Coepack^®^ is the most common and widely used non-eugenol dressing. Supplied as two pastes or as an auto-mixing system in syringe (Carranza & Saglie, [@CIT0011]). Coepack^®^ is prepared by mixing equal lengths of paste from tubes containing the accelerator and the base until the resulting paste is of uniform color. However, and in spite being a gold standard, Coepack^®^, was assessed together with other periodontal dressings for their physical and mechanical properties (Zahra & Mahdi, 2013) and it was found that the tested dressings including Coepack^®^ showed dimensional changes after completion of their setting which may lead to the distortion of the surgical area (Bhaskar et al., [@CIT0005]; Gjerdet & Haugen, [@CIT0018]). Regarding its adhesion properties, Coepack^®^ was found to be generally a poor bioadhesive, it is worth mentioning, that researchers highlighted the importance of this property for its role in the prevention of microbial penetration. In addition, Coepack^®,^ might not be always applied evenly to the area of the wound so that local concentrations will vary across the wound, especially if it is suppurating.

Poor bioadhesion and uneven distribution over the wound surface do not lend dressings such as Coepack^®^ to controlled or extended delivery and in turn, there becomes a growing need for novel formulations with improved physical properties and containing pharmacological agents, which take active part in a controlled wound healing process.

Wafers are formulations prepared by freeze-drying of polymeric solutions to yield solid porous structures that can easily be applied to suppurating wound surfaces (Matthews et al., [@CIT0028]) and have proven potential for mucosal wound healing (Ng & Jumaat, [@CIT0033]). Wafers offer multiple advantages over other wound delivery systems including tensile strength, hydration, bioadhesivity, rheological properties, resistance to compressive forces and controlled drug release characteristics, all combined critically influence the performance of formulations applied to moist surfaces (Boateng & Catanzano, [@CIT0006]). Due to their porous nature and higher surface area, they as well, have a higher drug loading capacity compared to films (Boateng et al., [@CIT0007]).

ALG and PVP K-25 were selected for wafer preparation for their expected inherent ability to form coherent and stable freeze-dried wafers (Matthews et al., [@CIT0026]).

Many studies have been conducted to investigate the effect of nonselective non-steroidal anti-inflammatory drugs (NSAIDs) to control postoperative pain after periodontal surgery, with generally favorable results (Betancourt et al., [@CIT0004]). Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug with an analgesic potency comparable with morphine, but without the opiate receptor-associated side effects (DiPalma, [@CIT0013]). The beneficial effects of ketorolac are probably due to its ability to block prostaglandin synthesis by preventing the conversion of arachidonic acid to the endoperoxides. Animal studies demonstrated that the analgesic activity of ketorolac results principally from a peripheral action (Buckley & Brogden, [@CIT0009]).

Lidocaine is one of the local anesthetics that are most widely used in surgical dental procedures today; when coming into contact with the nerve fiber it interrupts the propagation of the nerve impulse in a lasting and reversible manner (Pipa-Vallejo & Garcia-Pola-Vallejo, [@CIT0038]; Catanzano et al., [@CIT0012]).

The eventual aim of this work is to use two biocompatible inexpensive polymers to formulate a highly porous mucoadhesive structure capable of delivering and maintaining an effective concentration of a combination of ketorolac and lidocaine drugs to periodontal wound surfaces.

2.. Materials and methods {#s0002}
=========================

2.1.. Materials {#s0003}
---------------

Sodium alginate (ALG), polyvinylpyrrolidone K-25 (PVP K-25), and lactose were purchased from Sigma (St. Louis, MO). Ketorolac tromethamine was a kind gift from PHARCO Pharmaceutical Company (Alexandria, Egypt). Lidocaine HCl, a kind gift from MISR Pharmaceutical Company (Cairo, Egypt). Other materials were of analytical grade.

2.2.. Methods {#s0004}
-------------

### 2.2.1.. Preparation of wafers {#s0005}

Nine wafer formulae containing ketorolac tromethamine and lidocaine hydrochloride were prepared. Two different polymers were used in the preparation; ALG and PVP K-25 in three different polymeric ratios (1:1, 1:2, and 2:1). The effect of varying the concentrations of glycerol as plasticizer was tested (0, 5, and 10% of the dry weight). The calculated amount of ALG was dissolved in 30 mL distilled water under magnetic stirring and left in the refrigerator for 24 hours. Then, the required amount of PVP K-25 was added in the specified ratio with continuous stirring till it was completely dissolved and the polymeric solution was finally left in the refrigerator for another 24 hours to remove air bubbles. After which, ketorolac tromethamine (2%), lidocaine HCl (2%) and lactose (5%) have been added. Glycerol (0, 5, and 10% of the dry weight) was then added and homogenously mixed with the solutions ([Table 1](#t0001){ref-type="table"}). A specified amount of each of the produced solutions was poured in plastic rounded molds of 1.5 cm diameter and then lyophilized over a 30 h period from 25 °C to --50 °C and then back to 25 °C with a vacuum of 20 mTorr after initially being cooled from room temperature to --80 °C over a period of 24 h.

###### 

The design of the nine prepared formulae.

  Formula   SA:PVP (X1)   Glycerol % (X2)   Ketorolac   Lidocaine HCl   Lactose %
  --------- ------------- ----------------- ----------- --------------- -----------
  F1        1:1           0                 2%          2%              5
  F2        1:1           5                 2%          2%              5
  F3        1:1           10                2%          2%              5
  F4        2:1           0                 2%          2%              5
  F5        2:1           5                 2%          2%              5
  F6        2:1           10                2%          2%              5
  F7        1:2           0                 2%          2%              5
  F8        1:2           5                 2%          2%              5
  F9        1:2           10                2%          2%              5

### 2.2.2.. Characterization of wafers {#s0006}

#### 2.2.2.1.. Morphology using scanning electron microscopy (SEM) {#s0007}

Freeze-dried wafers were fixed in place by means of double sided copper electrical tape and gold coated. SEM images were obtained using a JEOL JXA-840A SEM (Tokyo, Japan).

#### 2.2.2.2.. Hydration capacity {#s0008}

The hydration capacity (HC) of the prepared wafers was carried out by incubating the samples at 37 ± 0.1 °C in 25 mL of PBS solution (pH 6.8). The wafers (*n* = 4) were initially weighed and the swelling behavior observed at predetermined time intervals (Wu et al., [@CIT0046]). The samples were removed, blotted off carefully between tissue papers to remove the surface-adhered liquid droplets and reweighed to constant weight. The percentage of water uptake was calculated as follows:$$\text{Water~uptake~}\left( \% \right) = \frac{100 \times \left( {Ws - W} \right)}{W}$$

where Ws is the weight of the hydrated wafer and *W* is the initial weight of wafer.

#### 2.2.2.3.. Drug incorporation efficiency {#s0009}

Each wafer was dissolved in 20 mL of phosphate buffer saline (PBS, pH 6.8). The resulting solutions were filtered using filter paper prior to analysis on a UV spectrophotometer to detect ketorolac and lidocaine concentrations at 318 nm and 265 nm wavelengths, respectively. The UV--visible spectrum of each ketorolac and lidocaine shows that they do not interfere with each other and therefore they can be quantitatively determined in the presence of each other (Fegade et al., [@CIT0016]).

Drug incorporation efficiency was expressed as drug entrapment (%) represented by the following equation:$$\text{EE~}\left( \% \right)\  = \frac{\text{Total~amount~of~drug~in~the~wafer}}{\text{Initial~amount~of~drug~taken~for~loading~studies}} \times 100$$

The individual values for three replicates were determined, and their mean values were reported.

#### 2.2.2.4.. Drug content uniformity analysis {#s0010}

Each wafer was cut into four equal sized pieces. Each piece was dissolved in 20 mL of PBS (pH 6.8). The resulting solutions were filtered using filter paper prior to analysis on a UV spectrophotometer to detect ketorolac and lidocaine concentrations at 318 nm and 265 nm wavelengths, respectively. The absorbance of each solution was measured against a blank solution, each experiment was carried out in triplicate.

#### 2.2.2.5.. In vitro release test {#s0011}

The nine wafers were assessed for their drug release profile. Each wafer was immersed in a beaker containing 50 mL PBS of pH 6.8 ± 0.1 as dissolution medium at 37 ± 0.1 °C with a stirring speed of 150 rpm applied with a magnetic stirrer, all beakers were covered throughout the experiment. Two milliliters of the dissolution medium were sampled at pre-determined time intervals and replenished with equal amounts of fresh medium to maintain a constant volume for 8 h. The concentration of each of ketorolac and lidocaine in each sample withdrawn from the dissolution medium was measured spectrophotometrically at wavelengths of 318 nm and 265 nm, respectively. The cumulative percentage of drugs' released over 8 h period was determined.

### 2.2.3.. Ex vivo mucoadhesion time {#s0012}

The mucoadhesion of wafer formulations was tested using the modified rotating cylinder method reported by Grabovac et al. ([@CIT0019]). A fresh chicken pouch membrane was used as model mucosa. Mucosa was inverted and threaded on a cylinder of 2 cm diameter. Each wafer was allowed to swell for 10 min in 50 mL of phosphate buffer pH 6.8 and then gently placed onto the mucosal surface. The assembly was immersed in a beaker containing 500 mL of phosphate buffer pH 6.8 at 37 °C, with 300 rpm rotation. Time required for the wafer to detach from the mucosal surface or time to its complete erosion from the mucosa was recorded as the mucoadhesion time (Patel et al., [@CIT0034]).

### 2.2.4.. Clinical study {#s0013}

This study was conducted on 20 patients, admitted to the outpatient clinic of the Faculty of Oral and Dental Medicine, MSA University. The study protocol and patients' consents were approved by the ethics committee, Faculty of Pharmacy, MSA University.

The age of patients ranged from 17 to 30 years, they all needed a soft tissue gingivectomy procedure in two quadrants of the maxillary anterior teeth. Patients received scalpel gingivectomies in the right quadrant of the arch needing treatment followed by Coepack application (group A), while on the left quadrant they received the same procedure but the wound was covered by the selected ketorolac/lidocaine wafer (group B).

*Inclusion criteria*. Patients enrolled into the study were those needing esthetic crown lengthening and classified as 'type 1' according to Ernesto esthetic Crown Lengthening classification (Ernesto, 2004).

*Exclusion criteria.* Patients excluded from the study were those:with history of antibiotic therapy in the past two months,with history of corticosteroid therapy in the past two months,on hormonal drugs in the past two months,with diabetes mellitus,with aggressive periodontitis,who smoke.

Patients were all free from any systemic diseases as evidenced by 'health questionnaire' using Cornell's index (Kerr & Millard, [@CIT0023]). They were not receiving any medication that could affect the healing of soft tissues and bones.

The wound progress after surgical procedure was assessed as follows.

#### 2.2.4.1.. Pain and discomfort assessment {#s0014}

This was done using 'Visual Analogue Scale' on the evening of the surgery and for the following six days.

Patients were given visual analog scales (VAS) which consists of a 100-mm line anchored by two extremes ('no pain' and 'pain as bad as it could be') to rate their pain. The patients were also asked to rate the degree of pain on two 10 cm horizontal VAS, one for the patient's right side and one for the left side. The left endpoint of the scale was designated as 'no pain' and the right endpoint designated as 'worst pain imaginable'. Patients were instructed to place a vertical mark at the position between the two endpoints that best described their personal perception of the pain they experienced on that particular side (Jensen et al., [@CIT0022]).

*Score interpretation*. To follow up the severity of postoperative pain, the patients were asked to correlate the pain to a 10-point VAS on each assessment day. The anchor words were 'no pain at all' equivalent to 0 and 'the most intense pain you can imagine' equivalent to 10. The patients were not shown the previous pain score recording. The patients were asked to score pain for left and right side. The mean and standard deviation of the VAS values were determined in each group. Data were analyzed with a paired *t* test (*p* value \<.05).

#### 2.2.4.2.. Wound healing assessment {#s0015}

This was done using 'wound healing index' (WHI) which was recorded after surgery and at 1 week, 2 weeks, and 4 weeks post-surgery. WHI was calculated according to the following scoring system.

Score 1: uneventful healing with no gingival edema, erythema, suppuration, patient discomfort, or flap dehiscence; Score 2: uneventful healing with slight gingival edema, erythema, patient discomfort, flap dehiscence, or any suppuration; and Score 3: poor wound healing with significant gingival edema, erythema, patient discomfort, flap dehiscence, or any suppuration (Wikesjö et al., [@CIT0045]; Huang et al., [@CIT0021]).

3.. Results {#s0016}
===========

3.1.. Preparation of wafers {#s0017}
---------------------------

Various wafer formulations listed in [Table 1](#t0001){ref-type="table"} contained different combinations of polymers and plasticizer. Wafers could be considered a balanced design for drug delivery to wound sites as it ensures long residence time while preventing damage to newly formed tissues (Boateng et al., [@CIT0007]). Lyophilization is a preferred drying method as it offers porous stable products, extends their shelf life and allows their further storage at room temperature instead of refrigeration (Bunte et al., [@CIT0010]).

Lyophilized wafers are made by freeze-drying gels containing therapeutic agents that would be applied to the mucosal surfaces (Matthews et al., [@CIT0027]). The wafers then return to a gel form once applied and provide sustained release of the drug (Boateng et al., [@CIT0007]). The porosity of the wafer adequately governs water uptake from the wound exudates and swells to maintain a moist healing environment, prevent cellular dehydration and facilitate collagen synthesis and angiogenesis to accelerate wound healing (Elsner & Zilberman, [@CIT0014]).

ALG is an anionic polysaccharide, extracted from brown algae (Phaeophyceae) or obtained by bacterial biosynthesis from *Azotobacter* and *Pseudomonas* spp. Depending on the block content, length and distribution in the polymeric chain, ALGs possess different physical, chemical and gelling properties (Pereira et al., [@CIT0037]). ALG dressings are characterized by the formation of a gel due to the exchange between the ions present in the dressing and wound exudate (Thomas et al., [@CIT0043]). This gel creates a moist environment that promotes healing and facilities easy removal (Boateng et al., [@CIT0008]). This together with its high tissue compatibility, low toxicity and good mucoadhesive properties allows ALGs to be used as biomaterials for wafers (Saarai et al., [@CIT0039]). Polymer PVP K-25 was incorporated with the ALG to modify the drug release profile and enhance its mucoadhesiveness (Hassan et al., [@CIT0020]).

3.2.. Characterization of wafers {#s0018}
--------------------------------

### 3.2.1.. Morphology using scanning electron microscopy {#s0019}

Scanning electron microscope results showed that the drug loaded formulations possessed an interconnecting polymeric network of sponge-like, uniform porous morphology. The average pore diameter ranged between 30 and 40 µm as shown in [Figure 2](#F0002){ref-type="fig"}. Drug particles loaded within the wafer structure appeared as crystalline depositions along the strands of the polymeric network ([Figure 1](#F0001){ref-type="fig"}).

![SEM micrographs of drug loaded wafers.](IDRD_A_1413445_F0001_B){#F0001}

### 3.2.2.. Hydration capacity {#s0020}

[Figure 2](#F0002){ref-type="fig"} shows the HC of the nine wafers under investigation. To assess the effect of glycerol concentration on the HC, formulations F1, F2, and F3 prepared with the same SA:PVP ratio but different glycerol concentrations were compared to each other, F3 was found to possess the highest HC. The same was reported with groups of formulations F4, F5, and F6 and F7, F8, and F9. The presence of high concentrations of glycerol in wafers F3, F6, and F9 has enhanced their hydration capacities compared to their relative formulations which might be attributed to glycerol causing an increase in the intermolecular spaces between the polymer chains allowing water accessibility, this was further supported by the 'inward-caving' (Ayensua et al., [@CIT0002]) of glycerol bearing wafers after lyophilization, this caving might have been created due to the enlarged spaces between the polymer chains by the plasticizer resulting in a loose structure capable of enhancing water absorption (Ayensua et al., [@CIT0002]). However, it was seen that increasing the PVP K-25 concentration resulted in a decrease in the HC in formula F7; recording the least HC in 120 min time. Generally, at pH of 6.8 (in which the experiment was carried out), the nitrogen atom of the PVP K-25 molecule will acquire a positive charge by protonation and in turn, will cross link with SA molecules (which carry a negative charge due to ionization). Therefore, generally, increased crosslinking is expected to decrease the HC of the wafer with higher PVP K-25 concentrations (as is the case in formula F9). Whereas, formulations F6 and F3 showed insignificantly different HCs which could be a reflection of the higher concentrations of SA in such formulations; exceeding the crosslinking capacity of PVP K-25; and thus, working freely to absorb water especially in formulations with high glycerol concentration (Miranda et al., [@CIT0030]; Abd El-Hady & Abd El-Rehim, [@CIT0001]).

![Wafers' hydration capacity.](IDRD_A_1413445_F0002_C){#F0002}

### 3.2.3.. Drug incorporation efficiency {#s0021}

Generally, wafers showed high drug content with no significant differences in drug content between different formulations where drug content ranged from 87.34 ± 1.60% to 93.25 ± 2.65% for ketorolac and from 86.14 ± 8.12 to 92.55 ± 11.20 for lidocaine in all tested wafers (*p*\>.05, ANOVA).

### 3.2.4.. Drug content uniformity analysis {#s0022}

Both drugs showed uniform content distribution within each of the tested wafers (*p*\>.05, ANOVA) which indicates the homogeneity of drug entrapment and subsequently, controlled drug release.

### 3.2.5.. In vitro release studies {#s0023}

The general high release percent of both ketorolac and lidocaine from wafers in 8 h time indicates that drug release is generally facilitated by the porous network of lyophilized wafers. The porous structure allows for an increased surface area of the dispersed drug and in turn accelerated dissolution (Bunte et al., [@CIT0010]).

As shown in [Figure 3](#F0003){ref-type="fig"}, the total cumulative percent ketorolac release in 8 h from all nine wafers ranged from 66.94 ± 1.8% to 98.14 ± 3.7% for formulations F7 and F6, respectively, which was statistically significant (*p*\<.05), though all formulations exhibited a sustained (controlled) release profile. In addition, the rate of release (indicated by the slope of the initial linear portion of the curve) was slower from the wafers containing 0% glycerol (F1, F4, and F7) within the first half an hour of release.

![(a) Cumulative percentage release of ketorolac from the nine wafer formulations and (b) cumulative percentage release of lidocaine from the nine wafer formulations.](IDRD_A_1413445_F0003_C){#F0003}

Generally, a similar trend accompanied the release of lidocaine from wafers. Lidocaine release percent ranged from 60.25 ± 2.12% from F7 to 100.76 ± 4.36% from F6.

Hydration and swelling are the main factors suggested to control the release of drugs in this study. Wafers with high ALG:PVP K-25 ratio and high glycerol percent (F6) showed faster drug release in the first hour, where, the addition of glycerol might have led to a loose and stable micro-porous structure which allowed easy hydration.

On the other hand, the low percent release of both drugs from F7 might be attributed to the combined high percentage of PVP K-25 and 0% glycerol in the formulation which could have affected the initial hydration of the wafer, thus, slowing down the rate of water access into the polymeric network and hampering to a great extent the release of drugs.

3.3.. *Ex vivo* mucoadhesion time {#s0024}
---------------------------------

The mucoadhesion of the prepared wafers at the buccal mucosa confirms their utility as buccal drug carriers since enhanced mucoadhesion results in prolonged drug residence time and thus, improved bioavailability and efficacy (Zaki et al., [@CIT0047]).

It has been generally reported that the hydration of polymer is essential for the relaxation and interpenetration of polymer chains but, excess hydration generally leads to decreased mucoadhesion due to the formation of slippery mucilage (Mortazavi & Smart, [@CIT0032]). As wafers uptake water, swelling starts, bonding starts and adhesion occurs. Initially, the bond formed will be weak but it is expected to increase with hydration. However, finally it reaches a point where over hydration leads to the disentanglement and distortion of polymer molecules at the interface and decreases the adhesion (Peh & Wong, [@CIT0036]).

As reported in [Table 2](#t0002){ref-type="table"}, F6 was found to have superior mucoadhesive time compared to other formulations. F3 came next whereas F7 came at the end of the list.

###### 

*Ex vivo* mucoadhesive time of the nine tested drug formulations.

  Formula   Mucoadhesive time (min)
  --------- -------------------------
  F1        263
  F2        299
  F3        339
  F4        301
  F5        310
  F6        364
  F7        242
  F8        287
  F9        321

This can be attributed to the higher concentration of ALG in formula F6. ALG has free hydroxyl groups available for hydrogen binding and is an anionic polymer with carboxylate functional groups that (when ionized) can interact electrostatically with the mucin coat. Furthermore, this could also be ascribed to the conformational arrangements of [d]{.smallcaps}-mannuronic acid (M blocks) and [l]{.smallcaps}-guluronic acid (G blocks) of ALG chains that are favorable for interaction with the mucin coat, as well as the high density of carboxylate groups (Skjåk-Braek, [@CIT0042]).

In spite of F9 and F7 having equal ratios of ALG:PVP K-25, it was clear that F9 had longer mucoadhesive time. This might be attributed to its high concentration of glycerin that contains large number of the hydrophilic hydroxyl groups, thus resulting in creation of a strong gel by the formation of abundance of hydrogen bonding that infiltrates intensely into the mucin layer (Mohamad et al., [@CIT0031]).

3.4.. Clinical study {#s0025}
--------------------

Split mouth design was chosen for the present study because it minimizes the inter-subject factors such as age, sex, anatomic factors and bone metabolism and any differences that may be present (Lobo & Pol, [@CIT0024]).

Based on the *in vitro* characterization results, F6 (2:1, ALG:PVP K-25 and 10% glycerol) was selected for the clinical study.

### 3.4.1.. Pain and discomfort assessment {#s0026}

Participants of both groups reported highest mean VAS scores (1.8 ± 0.41 and 1.7 ± 0.47 for groups A and B, respectively) on day 3. None of the participants reported mean VAS above 2. On day 6, mean VAS scores declined significantly for both groups (*p* \< .05). However, comparing VAS values of both groups on day 6, a statistically significant difference in favor of group B was observed (0.7 ± 0.47 vs. 0, for groups A and B, respectively, *p* \< .05).

The above findings could be explained as follows; the possibility to reduce post-surgical pain is among the main reasons for clinicians to cover the surgical site with dressing. In this respect, it has been claimed that the periodontal packs like Coepack^®^ may reduce post-operative pain and discomfort only by protecting the surgical site and they do not have therapeutic effects (Ghanbari et al., [@CIT0017]). On the other hand, topical formulations of NSAIDs developed in different dosage forms such as gels, toothpastes and rinses will not only produce a local anti-inflammatory effect at the infected sites (Salvi & Lang, [@CIT0041]) but can also reduce the systemic adverse effects of nonselective NSAIDs in long-term modulation of gingivitis and periodontitis-susceptible patients.

The relatively new wafer formulation of ketorolac/lidocaine offers not only a passive protection of the postsurgical wound, but, it provides a local anesthetic and anti-inflammatory drugs potentially delivered to the mucosal surface. Unlike semi solid polymer gels which flow easily after application, wafers, can maintain their swollen gel structure for a longer period and therefore, longer residence time to allow for effective treatment (Pawar et al., [@CIT0035]; Catanzano et al., [@CIT0012]). This might be the reason behind the slightly lower mean VAS levels on day 3 with the subsequent significant reduction on day six (reaching 0, *p* \< .05) in group B.

### 3.4.2.. Wound healing assessment {#s0027}

Results obtained at clinical evaluation of WHI performed using both Coepack^®^ and ketorolac/lidocaine wafer showed a significant improvement in healing of the wounds from week 1 postoperative through week 4 postoperative (*p* \< .05), with ketorolac/lidocaine wafer showing insignificantly lower WHI scoring vs. Coepack^®^ (1.0 vs. 1.5, respectively, *p* \> .05).

In [Figure 4](#F0004){ref-type="fig"}, the patient suffered from long standing gingival inflammation, the figure is taken immediately before surgery. [Figure 4(aL, aR)](#F0004){ref-type="fig"} shows the effect of using Coepack^®^ vs. ketorolac/lidocaine wafer, respectively, on inflammation and wound healing. It is clear that swelling and inflammation are reduced with no bruising detected in [Figure 4(RaR)](#F0004){ref-type="fig"} compared to [Figure 4(aL)](#F0004){ref-type="fig"}.

![Clinical photographs taken preoperatively and after 1 week post-operatively.](IDRD_A_1413445_F0004_C){#F0004}

4.. Conclusions {#s0028}
===============

On the basis of characterization and *in vitro* release of all nine wafer formulations, formula F6 containing 2:1 ALG to PVP K-25 and 10% glycerol was the formulation of choice for the clinical study. The study was conducted on 20 patients, comparing VAS values of both groups on day 6, a statistically significant difference in favor of group B (wafer group) was reported, while clinical evaluation of WHI performed using both Coepack^®^ and ketorolac/lidocaine wafer showed a significant improvement in healing of the wounds from week 1 postoperative through week 4 postoperative (*p* \< .05), with ketorolac/lidocaine wafer showing insignificantly lower WHI scoring vs. Coepack^®^. The developed ketorolac/lidocaine wafer could offer an effective method of reducing pain and discomfort and inflammation together with enhancing wound healing following gingivectomy.
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